Medical Devices

FDA clearance for Pulmera's CBeam platform could democratize surgery by turning standard 2D X-ray machines into advanced 3D imagers, slashing costs.

With a fresh $31M, Advanced NanoTherapies is advancing a first-of-its-kind dual-drug nanoparticle balloon, a technology poised to disrupt the market.

In a world of chip shortages and counterfeit risks, a new class of strategic partners has emerged. Here’s why your next product depends on them.

With a $1.25 billion investment from Apollo Funds, McKesson is spinning off its medical supply unit. Is this a cure for corporate bloat or a new symptom of financialization in healthcare?

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

The Dallas Cowboys are using a new device to build muscle. It’s part of a high-stakes trend where technology is redefining athlete recovery and longevity.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

A new partnership is democratizing science for wellness brands, making it faster and cheaper to prove their final products work and earn customer trust.

Penn Highlands Healthcare is offering up to $65K in loan repayment to build its workforce. Is this the new blueprint for solving talent shortages?

With dual FDA clearances secured, Rhythm AI appoints serial acquirer Mike Dineen as CEO, signaling a strategic pivot from innovation to market conquest.

A surprising innovation is changing surgical recovery. New research shows preoperative Botox can halve opioid use for jaw surgery patients. A breakthrough?

Pluri is moving its advanced cell-expansion tech from the lab to the lucrative U.S. aesthetics market. Is this a savvy commercial pivot or a risky gamble?

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

A new manufacturing deal sees Bluejay Diagnostics bet on U.S. resilience. It's a strategic retreat from global risk for a firm facing a long regulatory road.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

A pivotal trial completes enrollment at a record pace while the AMA lays the groundwork for billing. ShiraTronics is rewriting the medtech playbook.

A new startup, morph, is embedding intelligence into materials themselves. This isn't just another app—it's a systemic shift rewriting the rules of industry.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

A Japanese firm has achieved a breakthrough in manufacturing ultra-smooth capillary tubes, a tiny component set to unlock major advances in medicine and tech.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.